Demonstrates CERENOVUS' Continued Commitment to Reducing Disparities in Stroke Care with Actionable Best Practices for Closing Racial and Ethnic Gaps Along the Continuum of Care
Builds On Previously Published Research and Offers Interactive Tools for Effective Strategy Implementation
Irvine, CA – 6-13-2024 – CERENOVUS, Inc., an emerging leader in neurovascular care and part of Johnson & Johnson MedTech1, today announced the release of “Recommendations Aimed at Closing the Racial and Ethnic Disparity Gap in Stroke Care” as well as the accompanying online hub to support healthcare practitioners and administrators in their efforts. The study, led by Shelly Ikeme, Pharm.D., MPH, Head of the Health Economics and Market Access (HEMA) sector of CERENOVUS reviewed established hospital-level programs and best practices and offers recommendations for stroke care centers, empowering them to effectively address and reduce disparities in stroke access and care.
This review builds on a previous 2022 systematic literature review that identified racial disparities in key points along the continuum of stroke care, from onset of stroke symptoms to treatment. The previous work, titled “Evidence-Based Disparities in Stroke Care Metrics and Outcomes in the United States: A Systematic Review”, was published in STROKE. Drawing from the challenges previously identified, particularly those faced by communities of color in preventing and treating strokes, the new review presents a robust framework of best practices. This framework is designed to overcome imbalances in stroke care, marking a significant stride towards health equity.
“This review steps beyond the identification of disparities by providing recommendations to close racial and ethnic gaps in stroke care,” said William Humphries*, M.D., MPH. “The framework provides best practices from established programs to serve as a guide for care centers, enabling them to enhance stroke care outcomes for all patients, irrespective of their race or ethnicity.”
Among the summary of best practices, the review outlines several hospital and health system-oriented modifiable factors that can be influenced by adopting evidence-based practices to close the racial and ethnic disparities gap in stroke care and outcomes. Factors include referral, evaluation and transfer patterns; care process pathways; EMS use; language interpretation; and time to treat.
“These often-overlooked disparities have significant implications on health outcomes and quality of life for countless patients in underserved populations,” said Mahesh Jayaraman, M.D., President of the Society of NeuroInterventional Surgery. “By addressing disparities directly, CERENOVUS is not just acknowledging a problem, but actively working towards a solution to create a more equitable healthcare landscape.”
In addition, CERENOVUS is launching a digital health equity hub that contains its published research and interactive assets, designed to assist hospital leadership with implementing strategies and evaluating progress to close the gap on disparities in stroke care.
“Racial disparities remain a pressing concern in healthcare, highlighting the urgent need for equitable access, treatment, and outcomes for all individuals regardless of their racial or ethnic background,” said Mark Dickinson, Worldwide President, CERENOVUS. “Our mission is to change the trajectory of stroke, through our ongoing commitment to research that unveils disparities in stroke care.”
Hospitals and health systems may request unpublished data specific to their hospital and/or market by connecting with the CERENOVUS team here.
Read the new review and visit the CERENOVUS digital health equity hub here.
Media contact:
Ryan Carbain
732-232-9062
[email protected]
About CERENOVUS
CERENOVUS, Inc., part of Johnson & Johnson MedTech, is an emerging leader in neurovascular care. Our commitment to changing the trajectory of stroke is inspired by our long heritage and dedication to helping physicians protect people from a lifetime of hardship. CERENOVUS offers a broad portfolio of devices used in the endovascular treatment of hemorrhagic and ischemic stroke. For more information, visit cerenovus.com and connect on LinkedIn and X.
About Johnson & Johnson MedTechi
At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized. For more information, visit thenext.jnjmedtech.com.
© CERENOVUS, Inc. 2024. All rights reserved. US_CNV_ALLC_302252.1
- CERENOVUS, Inc. is a part of Johnson & Johnson MedTech which comprises the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment
* Dr. Humphries is a paid consultant for CERENOVUS